StreetInsider.com News Articles

Aktis Oncology (AKTS) PT Raised to $33 at JPMorgan

Tue, 14 Jul 2026 07:42:20 -0400

JPMorgan analyst Jessica Fye raised the price target on Aktis Oncology (NASDAQ: AKTS) to $33.00 (from $30.00) while maintaining a Overweight rating.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

The analyst comments "We are initiating coverage of AKTS shares with a Strong Buy rating and $40 price target. With the targeted radiopharma field growing rapidly, we believe a strongly differentiated approach in the space is ideally poised to command investor attention. To that end, we think Aktis’s miniprotein-enabled radioligand therapy (RLT) platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches. Miniproteins are

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)

Mon, 15 Jun 2026 16:09:21 -0400

(Updated - June 15, 2026 4:09 PM EDT)

Raymond James analyst Chris Raymond initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Strong Buy rating and a price target of $40.00.

Akoustis Technologies (AKTS) PT Raised to $35 at H.C. Wainwright

Wed, 03 Jun 2026 06:50:41 -0400

(Updated - June 3, 2026 6:50 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Akoustis Technologies (NASDAQ: AKTS) to $35.00 (from $33.00) while maintaining a Buy rating.

The analyst commented: "At ASCO 2026, Aktis Oncology presented biodistribution and dosimetry results for AKY-2519. As shown in the two posters, AKY-2519's uptake in critical normal tissues is well below the normal-tissue dose limit thresholds (see Figure 1 below and Figure 3 overleaf); notably, the low predicted absorbed dose to salivary glands may differentiate an AKY-2519 RCT from other PSMA-targeted agents. The compound also displayed robust uptake and retention in a

Akoustis Technologies (AKTS) PT Raised to $35 at H.C. Wainwright

Wed, 03 Jun 2026 06:50:41 -0400

(Updated - June 3, 2026 6:50 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Akoustis Technologies (NASDAQ: AKTS) to $35.00 (from $33.00) while maintaining a Buy rating.

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at

Aktis reports imaging data for cancer drug targeting B7-H3 protein

Thu, 21 May 2026 17:36:37 -0400

Aktis Oncology Inc. (NASDAQ: AKTS) released first-in-human clinical imaging and dosimetry data for AKY-2519, a radioconjugate targeting B7-H3 expressing tumors. The data will be presented at the 2026 American Society of Clinical Oncology Annual Meeting from May 29 to June 2 in Chicago.

Two separate assessments evaluated AKY-2519 in patients with metastatic castration-resistant prostate cancer and various solid tumor types. The studies demonstrated tumor uptake and normal tissue exposure levels, according to the company's statement.

The first assessment, conducted at the University of Pretoria and Steve Biko Academic Hospital in South Africa, evaluated 16 patients with metastatic castration-resistant prostate cancer. Patients received

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Thu, 21 May 2026 17:21:00 -0400

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer (mCRPC), suggest a potentially differentiated profile compared to approved radiopharmaceuticals
Aktis to hold conference call on Wednesday, May 27, 2026, at 8:00 a.m. ET with leading clinical investigators, Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D., to discuss results